Biobanking and pharmacogenomics

Catherine A. McCarty, Russell A. Wilke

Research output: Contribution to journalComment/debatepeer-review

32 Scopus citations

Abstract

The study of genetic determinants underlying drug outcome is rapidly advancing. Initial success was realized within the context of candidate pharmacokinetic genes and serious adverse drug reactions, particularly for drugs with narrow therapeutic indices. Although genetic predictors of outcome have proven useful in other contexts, effect size has typically been small. To address these challenges, the clinical and scientific communities have begun studying larger numbers of gene variants (often at the genome-wide level) in cohorts of increasing sample size. Electronic health records are being increasingly used for this purpose. Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.

Original languageEnglish (US)
Pages (from-to)637-641
Number of pages5
JournalPharmacogenomics
Volume11
Issue number5
DOIs
StatePublished - May 2010

Keywords

  • Biobank
  • Electronic health record
  • GWAS
  • Personalized medicine
  • Pharmacogenomics

Fingerprint

Dive into the research topics of 'Biobanking and pharmacogenomics'. Together they form a unique fingerprint.

Cite this